{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T17:40:34Z","timestamp":1769276434646,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003665","name":"National IT Industry Promotion Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.clgc.2025.102473","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T14:15:17Z","timestamp":1763648117000},"page":"102473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Toxicity Comparison between a Four-Week Moderate Hypofractionation and a Six-Week Conventional Fractionation in the Post-Prostatectomy Salvage Radiotherapy for Prostate Cancer"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3420-022X","authenticated-orcid":false,"given":"Ha Un","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4152-9945","authenticated-orcid":false,"given":"Jaeha","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon Young","family":"Jo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4592-6539","authenticated-orcid":false,"given":"Sumin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2858-0644","authenticated-orcid":false,"given":"Yeon Joo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2025.102473_bib0001","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1001\/jama.299.23.2760","article-title":"Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy","volume":"299","author":"Trock","year":"2008","journal-title":"Jama"},{"key":"10.1016\/j.clgc.2025.102473_bib0002","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(20)31952-8","article-title":"Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data","volume":"396","author":"Vale","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.clgc.2025.102473_bib0003","unstructured":"EAU Guidelines. Edn. Presented at the EAU Annual Congress Paris, 2024; Available from: https:\/\/uroweb.org\/guideline\/prostate-cancer\/. Accessed on December 10, 2024."},{"key":"10.1016\/j.clgc.2025.102473_bib0004","unstructured":"NCCN guidelines Prostate Cancer. 2024; Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Accessed on December 10, 2024."},{"key":"10.1016\/j.clgc.2025.102473_bib0005","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ijrobp.2009.10.008","article-title":"Confirmation of a low \u03b1\/\u03b2 ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics","volume":"79","author":"Proust-Lima","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clgc.2025.102473_bib0006","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.ijrobp.2010.10.075","article-title":"Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: \u03b1\/\u03b2\u202f=\u202f1.4 (0.9-2.2) Gy","volume":"82","author":"Miralbell","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clgc.2025.102473_bib0007","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2025.102473_bib0008","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(16)30070-5","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial","volume":"17","author":"Incrocci","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2025.102473_bib0009","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2147\/CMAR.S146131","article-title":"Moderate hypofractionated radiotherapy after prostatectomy for cancer patients: toxicity and clinical outcome","volume":"10","author":"Barra","year":"2018","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.clgc.2025.102473_bib0010","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00066-020-01691-z","article-title":"Moderate hypofractionated radiotherapy for post-operative treatment of prostate cancer: long-term outcome and pattern of toxicity","volume":"197","author":"Franzese","year":"2021","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.clgc.2025.102473_bib0011","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.radonc.2022.03.006","article-title":"Moderate hypofractionation for salvage radiotherapy (HYPO-SRT) in patients with biochemical recurrence after prostatectomy: A cohort study with meta-analysis","volume":"171","author":"Viani","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clgc.2025.102473_bib0012","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ijrobp.2018.08.016","article-title":"Acute Toxicity Profiles of Hypofractionated Adjuvant and Salvage Radiation Therapy After Radical Prostatectomy: Results of a Prospective Study","volume":"103","author":"Saldi","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clgc.2025.102473_bib0013","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ijrobp.2018.02.002","article-title":"Postoperative Radiation Therapy for Prostate Cancer: Comparison of Conventional Versus Hypofractionated Radiation Regimens","volume":"101","author":"Tandberg","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clgc.2025.102473_bib0014","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13014-021-01808-3","article-title":"Comparison of hypofractionation and standard fractionation for post-prostatectomy salvage radiotherapy in patients with persistent PSA: single institution experience","volume":"16","author":"Murgic","year":"2021","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.clgc.2025.102473_bib0015","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0360-3016(94)90138-4","article-title":"Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and gleason score in men with clinically localized prostate cancer","volume":"28","author":"Roach","year":"1994","journal-title":"International Journal of Radiation Oncology*Biology*Physics"},{"key":"10.1016\/j.clgc.2025.102473_bib0016","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ijrobp.2009.02.006","article-title":"Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer","volume":"76","author":"Michalski","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clgc.2025.102473_bib0017","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3857\/roj.2013.31.4.199","article-title":"Whole pelvic intensity-modulated radiotherapy for high-risk prostate cancer: a preliminary report","volume":"31","author":"Joo","year":"2013","journal-title":"Radiation oncology journal"},{"key":"10.1016\/j.clgc.2025.102473_bib0018","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/jrr\/rraa074","article-title":"The effects of PSA kinetics on the outcome of hypofractionated salvage radiotherapy for biochemical recurrence of prostate cancer after prostatectomy","volume":"61","author":"Ishikawa","year":"2020","journal-title":"Journal of Radiation Research"},{"key":"10.1016\/j.clgc.2025.102473_bib0020","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ijrobp.2023.04.032","article-title":"Salvage Radiation Therapy After Radical Prostatectomy: Analysis of Toxicity by Dose-Fractionation in the RADICALS-RT Trial","volume":"117","author":"Petersen","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clgc.2025.102473_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102102","article-title":"10-yr Results of Moderately Hypofractionated Postoperative Radiotherapy for Prostate Cancer Focused on Treatment Related Toxicity","volume":"22","author":"Castelluccia","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2025.102473_bib0022","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1001\/jamaoncol.2023.7291","article-title":"Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical Trial","volume":"10","author":"Buyyounouski","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clgc.2025.102473_bib0023","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.2147\/CMAR.S182016","article-title":"Hypofractionated postoperative helical tomotherapy in prostate cancer: a mono-institutional report of toxicity and clinical outcomes","volume":"10","author":"Cuccia","year":"2018","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.clgc.2025.102473_bib0024","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3390\/cancers14051320","article-title":"Impact of dose escalation on the efficacy of salvage radiotherapy for recurrent prostate cancer\u2014a risk-adjusted, matched-pair analysis","volume":"14","author":"B\u00f6hmer","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.clgc.2025.102473_bib0025","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1186\/s13063-021-05708-5","article-title":"Salvage hypofractionated accelerated versus standard radiotherapy for the treatment of biochemical recurrence after radical prostatectomy (SHARE): The protocol of a prospective, randomized, open-label, superiority, multi-institutional trial","volume":"22","author":"Park","year":"2021","journal-title":"Trials"},{"key":"10.1016\/j.clgc.2025.102473_bib0026","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.eururo.2021.05.033","article-title":"Dose-intensified versus conventional-dose salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: the SAKK 09\/10 randomized phase 3 trial","volume":"80","author":"Ghadjar","year":"2021","journal-title":"European urology"},{"key":"10.1016\/j.clgc.2025.102473_bib0027","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","article-title":"The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial","volume":"399","author":"Pollack","year":"2022","journal-title":"The Lancet"},{"key":"10.1016\/j.clgc.2025.102473_bib0028","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.ijrobp.2014.12.017","article-title":"Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients","volume":"91","author":"Wortel","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clgc.2025.102473_bib0029","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1748-717X-9-44","article-title":"Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance","volume":"9","author":"Sveistrup","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.clgc.2025.102473_bib0030","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.ijrobp.2018.07.2006","article-title":"Daily Versus Weekly Prostate Cancer Image Guided Radiation Therapy: Phase 3 Multicenter Randomized Trial","volume":"102","author":"de Crevoisier","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clgc.2025.102473_bib0031","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.radonc.2010.04.016","article-title":"Is there a role for endorectal balloons in prostate radiotherapy? A systematic review","volume":"95","author":"Smeenk","year":"2010","journal-title":"Radiother Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325001739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T03:42:21Z","timestamp":1769226141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325001739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1558767325001739"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102473","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicity Comparison between a Four-Week Moderate Hypofractionation and a Six-Week Conventional Fractionation in the Post-Prostatectomy Salvage Radiotherapy for Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102473","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102473"}}